U.S. Markets closed

The hodgkin's lymphoma drugs market will register a CAGR of close to 16% by 2023

NEW YORK, March 12, 2019 /PRNewswire/ -- About this market
Hodgkin's lymphoma is one of the most curable forms of lymphoma, with a patient survival rate of more than five years. The high unmet need for novel and innovative alternative treatment approaches. In addition, the introduction of target molecular hallmarks of this disease, including the aberrant phenotype of cancer cells, deregulated cancer pathways, and immune escape mechanisms. With an increased understanding of the fundamental biology of Hodgkin's lymphoma, companies have been able to develop drugs that are effective in treating the disease. This is expected to drive the market growth during the forecast period. Our analysts have predicted that the hodgkin's lymphoma drugs market will register a CAGR of close to 16% by 2023.

Read the full report: https://www.reportlinker.com/p05751906

Market Overview
Development of novel pipeline drugs
The increase in the prevalence of Hodgkin's lymphoma has led to a high unmet need for a strong pipeline of disease-modifying drugs. R&D activities are resulting in the availability of new drugs for the treatment of Hodgkin's lymphoma.
Treatment of Hodgkin's lymphoma patients with conjoint conditions
The treatment of Hodgkin's lymphoma has generally been successful and well-tolerated by patients. However, there are challenges associated with the treatment of patients that have Hodgkin's lymphoma with conjoint conditions, such as cardiac diseases, HIV infection, and pregnancy. Hodgkin's lymphoma is more common in patients with HIV. The presence of HIV in patients with Hodgkin's lymphoma can have a negative impact on treatment tolerance and prognosis.
For the detailed list of factors that will drive and challenge the growth of the Hodgkin's lymphoma drugs market during the 2019-2023, view our report.

Competitive Landscape
The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Read the full report: https://www.reportlinker.com/p05751906

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision

View original content:http://www.prnewswire.com/news-releases/the-hodgkins-lymphoma-drugs-market-will-register-a-cagr-of-close-to-16-by-2023-300810938.html